Merlin is a potent inhibitor of glioma growth

Cancer Research

Volumn 68, Issue 14, 2008, Pages 5733-5742

  Lau, Ying Ka Ingar ^a   Murray, Lucas B ^a   Houshmandi, Sean S ^b   Xu, Yin ^a   Gutmann, David H ^b   Yu, Qin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; MERLIN; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE LOSS; GENE MUTATION; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; BRAIN TUMOR; CANCER TRANSPLANTATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; MUTATION; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MICE; MUTATION; NEOPLASM TRANSPLANTATION; NEUROFIBROMIN 2; WNT PROTEINS;

EID: 48649109725     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0190     Document Type: Article

References (49)

1. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311-33.
2. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973-1991. J Neurosurg 1998;88:1-10.
3. Gutmann DH, Giordano MJ, Fishback AS, Guha A. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology 1997;49:267-70.
4. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515-21.
5. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:1-20.
6. Bretscher A, Chambers D, Nguyen R, Reczek D. ERM-Merlin and EBP50 protein families in plasma membrane organization and function. Annu Rev Cell Dev Biol 2000;16:113-43.
7. Gautreau A, Louvard D, Arpin M. ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr Opin Cell Biol 2002;14:104-9.
8. McClatchey AI. Merlin and ERM proteins: unappreciated roles in cancer development? Nat Rev Cancer 2003;3:877-83.
9. Bianchi AB, Hara T, Ramesh V, et al. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet 1994;6:185-92.
10. Sherman L, Xu H-M, Geist RT, et al. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 1997;15:2505-9.
11. Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21 activated kinase, Pak1. Mol Cell 2003;12:841-9.
12. Houshmandi SS, Surace EI, Zhang HB, Fuller GN, Gutmann DH. Tumor suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor. Neurology 2006;67:1863-6.
13. Bai Y, Liu YJ, Wang H, Xu Y, Stamenkovic I, Yu Q. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene 2007;26:836-50.
14. Liu YJ, Xu Y, Yu Q. Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 2006;25:2452-67.
15. Tang X, Jang SW, Wang X, et al. Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol 2007;9:1199-207.
16. Park CM, Park MJ, Kwak HJ, et al. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 2006;66:8511-9.
17. Kao GD, Jiang Z, Fernandes AM, Gupta AK, Maity A. Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem 2007;282:21206-12.
18. Alonso ME, Bello MJ, Arjona D, et al. Analysis of the NF2 gene in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 2002;134:1-5.
19. Liu X, Shi Y, Giranda VL, Luo Y. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis. Mol Cancer Ther 2006;5:494-501.
20. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 2005;117:755-63.
21. Aggarwal BB, Bhardwaj U, Takada Y. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Vitam Horm 2004;67:453-83.
22. Bredel M, Bredel C, Juric D, et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 2005;65:8679-89.
23. Shaw RJ, Paez JG, Curto M, et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 2001;1:63-72.
24. Lee H, Kim D, Dan HC, et al. Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein. Mol Cell Biol 2007;27:2103-19.
25. Chadee DN, Xu D, Hung G, et al. Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc Natl Acad Sci U S A 2006;103:4463-8.
26. Hamaratoglu F, Willecke M, Kango-Singh M, et al. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 2006;8:27-36.
27. McCartney BM, Kulikauskas RM, LaJeunesse DR, Fehon RG. The neurofibromatosis-2 homologue, Merlin, and the tumor suppressor expanded function together in Drosophila to regulate cell proliferation and differentiation. Development 2000;127:1315-24.
28. Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell 2005;122:421-34.
29. Pellock BJ, Buff E, White K, Hariharan IK. The Drosophila tumor suppressors expanded and merlin differentially regulate cell cycle exit, apoptosis, and wingless signaling. Dev Biol 2007;304:102-15.
30. Cho E, Feng Y, Rauskolb C, Maitra S, Fehon R, Irvine KD. Delineation of a Fat tumor suppressor pathway. Nat Genet 2006;38:1142-50.
31. Maitra S, Kulikauskas RM, Gavilan H, Fehon RG. The tumor suppressors merlin and expanded function cooperatively to modulate receptor endocytosis and signaling. Curr Biol 2006;16:702-9.
32. Creasy CL, Chernoff J. Cloning and characterization of a member of the MST subfamily of Ste20-like kinases. Gene 1995;167:303-6.
33. Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, Oren M. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev2006;20:26 87-700.
34. Takahashi Y, Miyoshi Y, Takahata C, et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005;11:1380-5.
35. Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006;103:12405-10.
36. Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA, Sillje HH. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 2005;24:2076-86.
37. Li Y, Pei J, Xia H, Ke H, Wang H, Tao W. Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene 2003;22:4398-405.
38. St John MA, Tao W, Fei X, et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 1999;21:182-6.
39. McPherson JP, Tamblyn L, Elia A, et al. Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. EMBO J 2004;23:3677-88.
40. Jiang Z, Li X, Hu J, et al. Promoter hypermethylationmediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 2006;56:450-8.
41. Zender L, Spector MS, Xue W, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006;125:1253-67.
42. Wu S, Huang J, Dong J, Pan D. hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 2003;114:445-6.
43. Tao W, Zhang S, Turenchalk GS, et al. Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nat Genet 1999;21:177-81.
44. Vlad A, Röhrs S, Klein-Hitpass L, Müller O. The first five years of the Wnt targetome. Cell Signal 2007 Nov 17 [Epub ahead of print].
45. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and β-catenin signaling: diseases and therapies. Nat Rev Genet 2004;5:691-701.
46. Kawano Y, Kypta R. Secreted antagonists of the Wnt signaling pathway. J Cell Sci 2003;116:2627-34.
47. Zhang Z, Schittenhelm J, Guo K, et al. Up-regulation of frizzled 9 in astrocytomas. Neuropathol Appl Neurobiol 2006;32:615-24.
48. Jozwiak J, Kotulska K, Grajkowska W, et al. Upregulation of the WNT pathway in tuberous sclerosis-associated subependymal giant cell astrocytomas. Brain Dev2007;29:27 3-80.
49. Shou J, Ali-Osman F, Multani AS, Pathak S, Fedi P, Srivenugopal KS. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene 2002;21:878-89.